GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » BioPlus Acquisition Corp (NAS:BIOS) » Definitions » EV-to-EBITDA

BioPlus Acquisition (BioPlus Acquisition) EV-to-EBITDA : -99.13 (As of May. 06, 2024)


View and export this data going back to 2022. Start your Free Trial

What is BioPlus Acquisition EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BioPlus Acquisition's enterprise value is $214.32 Mil. BioPlus Acquisition's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-2.16 Mil. Therefore, BioPlus Acquisition's EV-to-EBITDA for today is -99.13.

The historical rank and industry rank for BioPlus Acquisition's EV-to-EBITDA or its related term are showing as below:

BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -538.77   Med: 0   Max: 0
Current: -99.13

BIOS's EV-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 8.715 vs BIOS: -99.13

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), BioPlus Acquisition's stock price is $10.795. BioPlus Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $0.207. Therefore, BioPlus Acquisition's PE Ratio for today is 52.15.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


BioPlus Acquisition EV-to-EBITDA Historical Data

The historical data trend for BioPlus Acquisition's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPlus Acquisition EV-to-EBITDA Chart

BioPlus Acquisition Annual Data
Trend Dec21 Dec22
EV-to-EBITDA
- -259.96

BioPlus Acquisition Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -525.84 -351.47 -259.96 -273.25 -97.83

Competitive Comparison of BioPlus Acquisition's EV-to-EBITDA

For the Shell Companies subindustry, BioPlus Acquisition's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPlus Acquisition's EV-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, BioPlus Acquisition's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioPlus Acquisition's EV-to-EBITDA falls into.



BioPlus Acquisition EV-to-EBITDA Calculation

BioPlus Acquisition's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=214.319/-2.162
=-99.13

BioPlus Acquisition's current Enterprise Value is $214.32 Mil.
BioPlus Acquisition's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioPlus Acquisition  (NAS:BIOS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BioPlus Acquisition's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=10.795/0.207
=52.15

BioPlus Acquisition's share price for today is $10.795.
BioPlus Acquisition's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.207.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


BioPlus Acquisition EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioPlus Acquisition's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPlus Acquisition (BioPlus Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
260 Madison Avenue, Suite 800, New York, NY, USA, 10026
Website
BioPlus Acquisition Corp is a blank check company.
Executives
Steven C. Fletcher 10 percent owner C/O LEE ENTERPRISES, INCORPORATED, 4600 EAST 53RD STREET, DAVENPORT IA 52807
Explorer Parent Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Founder Holdings Llc 10 percent owner 533 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94012
Alex Serge Vieux 10 percent owner C/O COMPUTER ASSOCIATES INTER INC, ONE COMPUTER ASSOC PLAZA, ISLANDIA NY 11749
Bioplus Sponsor Llc 10 percent owner 544 AIRPORT BOULEVARD, SUITE 400, BURLINGAME CA 94010
Stephen A Sherwin director C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080
Louis G Lange director 3172 PORTER DRIVE, PALO ALTO CA 94034
Ross Haghighat director, officer: CEO and CFO C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Ronald W Eastman director 335 BRYANT STREET, THIRD FLOOR, PALO ALTO CA 94301
Shawn Cross director 1825 K STREET SUITE 510, WASHINGTON DC 20006
Jonathan Rigby director, officer: Chief Business Officer ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Glen Giovannetti director UNIT 6706, THE CENTER, 99 QUEEN'S ROAD CENTRAL, HONG KONG K3 00000